Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 7/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.72 |
| ▸ | NOS1 | P29475 | 2/20 | 0.61 |
| ▸ | NOS3 | P29474 | 1/20 | 0.61 |
| ▸ | NOS2 | P35228 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31389041 | 1.00 | PSMB8 (0.72) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL31389040 | 0.84 | PSMB8 (1.00) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL799525 | 0.84 | PSMB8 (1.00) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL12716526 | 0.79 | KDM4E (0.82) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL10897160 | 0.78 | PSMB8 (0.63) | PSMB8KEAP1KDM4EGAAMEN1 | |
| SCHEMBL4704344 | 0.76 | PSMB8 (0.61) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL780268 | 0.76 | PSMB8 (0.61) | PSMB8KEAP1KDM4EGAAMEN1 | |
| SCHEMBL777690 | 0.76 | PSMB8 (1.00) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL243203 | 0.76 | NOS1 (1.00) | PSMB8KEAP1NOS1NOS3NOS2 | |
| SCHEMBL14403384 | 0.76 | PSMB8 (0.72) | PSMB8KEAP1KDM4EGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312878-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-20230312878-A1 | RUBBER COMPOSITION AND CROSSLINKED RUBBER MOLDED PRODUCT | SUMITOMO RUBBER INDUSTRIES, LTD. (JP) | 2023-10-05 | — | — | US | disclosed |
| US-9249102-B2 | Anthelmintic compounds and compositions and method of using thereof | MERIAL, INC. (US) | 2016-02-02 | — | — | US | disclosed |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | MERIAL LIMITED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-16 | — | — | US | disclosed |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | SUMMIT CORPORATION PLC (GB) | 2014-01-09 | — | — | US | disclosed |
| US-8501713-B2 | Drug combinations for the treatment of duchenne muscular dystrophy | SUMMIT CORPORATION PLC (GB) | 2013-08-06 | — | — | US | disclosed |
| US-8273770-B2 | 5-pyridinone substituted indazoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2176251-B1 | 5-pyridinone substituted indazoles and pharmaceutical compositions thereof | ALBANY MOLECULAR RES INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | SUMMIT (OXFORD) LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | ROCHE PALO ALTO LLC | 2005-04-28 | — | — | US | disclosed |
| EP-1480959-A1 | PIPERAZINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2004-12-01 | — | — | EP | disclosed |
| EP-1465638-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| US-20040019113-A1 | Phosphate transport inhibitors | GELTEX PHARMACEUTICALS, INC. | 2004-01-29 | — | — | US | disclosed |
| WO-2003068759-A1 | PIPERAZINE DERIVATIVES AS ANTI-INFLAMMATORY AGENTS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| WO-2003057225-A2 | PHOSPHATE TRANSPORT INHIBITORS | GENZYME CORPORATION (US) | 2003-07-17 | — | — | WO | disclosed |
| US-4447522-A | INCLUDING A HYDRAZIDE AND A MERCAPTO AMINE IN THE SILVER HALIDE EMULSION LAYER; LITHOGRAPHY | FUJI PHOTO FILM CO., LTD. (JP) | 1984-05-08 | — | — | US | disclosed |
| US-4429036-A | DEVELOPMENT WITH ALKALINE AQUEOUS ACTIVATOR SOLUTION | FUJI PHOTO FILM CO., LTD. (JP) | 1984-01-31 | — | — | US | disclosed |
| US-4216284-A | NONDIFFUSIBLE SILVER BLEACH INHIBITOR | FUJI PHOTO FILM CO., LTD. (JP) | 1980-08-05 | — | — | US | disclosed |
| US-4001020-A | DEVELOPING A SILVER HA1IDE EMULSION IN CONTACT WITH A HETEROCYCLIC THIONE AND A POLYALKYLENE OXIDE | FUJI PHOTO FILM CO., LTD. (JA) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019113-A1 | Phosphate transport inhibitors | SLC34A1, SLC34A2, SLC20A1 | PSMB8 2715/4885KEAP1 3372/4885NOS1 4266/4885 |
| US-20110195932-A1 | Drug Combinations for the Treatment of Duchenne Muscular Dystrophy | PYGM, CPT1B, GYS1 | PSMB8 564/4885KEAP1 2233/4885NOS1 3432/4885 |
| US-20140011782-A1 | DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | PYGM, CPT1B, GYS1 | PSMB8 564/4885KEAP1 2233/4885NOS1 3432/4885 |
| US-20140142114-A1 | ANTHELMINTIC COMPOUNDS AND COMPOSITIONS AND METHOD OF USING THEREOF | CYP3A5, ABCC5, CXXC5 | PSMB8 1206/4885KEAP1 633/4885NOS1 4409/4885 |
| US-20050090504-A1 | Piperidinyl and piperazinyl compounds substituted with bicyclo-heterocyclylalkyl groups useful as CCR3 receptor antagonists | CCR9, CCR3, CCR1 | PSMB8 846/4885KEAP1 1608/4885NOS1 3831/4885 |
| US-20140018320-A1 | TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY | NR0B1, NR0B2, NR3C1 | PSMB8 952/4885KEAP1 3037/4885NOS1 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.